BF Biosciences Limited (PSX: BFBIO) has announced the successful commissioning of its combi filling and lyophilization lines, marking the start of commercial production. In a notice to the Pakistan Stock Exchange (PSX), the company referenced an earlier communication regarding its brownfield expansion project, which had received approval from the Drug Regulatory Authority of Pakistan (DRAP).

This approval also included the commencement of commercial production from its pre-filled syringes line.

The company stated, “In continuation of the above, we are pleased to inform that the combi filling and lyophilization lines have been commissioned and commercial production has commenced. Accordingly, the full Line II expansion project stands commissioned from today.”

Additionally, BF Biosciences has secured approvals for new products from DRAP and plans to launch these products in the coming months.